LAG3 Antibody [9F9] | RF16084

LAG3 Antibody [9F9] | RF16084 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: LAG-3 antibody was raised against the extracellular domain of human LAG-3

Research Area: Immunology

Tested Application: E, IHC-P, ICC, IF, Flow

Application: LAG-3 antibody can be used for ELISA starting at 0.25 μg/mL. For Immunocytochemistry start at 1 μg/mL. For Immunofluorescence start at 10 μg/mL. For Immunohistochemistry start at 5 μg/mL. For Flow Cytometry start at 1 μg/ml.
Antibody validated: Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1331 - Human Lymphoma Tissue Lysate

Positive Control 2: Cat. No. 1306 - Human Spleen Tissue

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: LAG-3 Antibody is supplied as protein A purified IgG2a.

Clonality: Monoclonal

Clone: 9F9

Isotype: IgG2a, k

Conjugate: Unconjugated

Physical State: Liquid

Buffer: LAG-3 Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.

Concentration: 1 mg/mL

Storage Condition: LAG-3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: LAG3 Antibody: lymphocyte activating 3, LAG-3, CD223

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1) , negatively regulating T-cell function and homeostasis (2) . It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3) , and acts to regulate T cell expansion (4) . LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy.